Manatuck Hill Partners, LLC Dia Medica Therapeutics Inc. Transaction History

Manatuck Hill Partners, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$2.29 - $3.88 $331,592 - $561,824	-144,800 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$3.43 - $4.65 $440,069 - $596,595	-128,300 Reduced 46.98%	144,800 $540,000
Q3 2021 Nov 15, 2021	SELL	$3.1 - $4.32 $921,940 - $1.28 Million	-297,400 Reduced 52.13%	273,100 $1.1 Million
Q1 2021 May 14, 2021	SELL	$7.76 - $10.43 $7,760 - $10,430	-1,000 Reduced 0.17%	570,500 $5.22 Million
Q3 2020 Nov 16, 2020	BUY	$3.91 - $7.15 $861,764 - $1.58 Million	220,400 Added 62.77%	571,500 $2.42 Million
Q1 2020 May 15, 2020	BUY	$2.25 - $5.64 $177,075 - $443,868	78,700 Added 28.89%	351,100 $983,000
Q3 2019 Nov 14, 2019	BUY	$2.07 - $4.88 $10,557 - $24,888	5,100 Added 1.91%	272,400 $564,000
Q2 2019 Aug 14, 2019	BUY	$2.7 - $4.96 $312,660 - $574,368	115,800 Added 76.44%	267,300 $1.33 Million
Q1 2019 May 15, 2019	SELL	$3.1 - $4.54 $150,350 - $220,190	-48,500 Reduced 24.25%	151,500 $688,000
Q4 2018 Feb 14, 2019	BUY	$2.65 - $9.2 $530,000 - $1.84 Million	200,000 New	200,000 $582,000

3.87M

1.3K

Ticker DMAC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 26,443,100
Market Cap $116M
Description
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type...

Get notified when there are updates to the investment portfolio of Manatuck Hill Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Manatuck Hill Partners, LLC with notifications on news.